Royalty Report: Drugs, Pain, Pharmaceuticals – Collection: 362680

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 14

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14

Primary Industries

  • Drugs
  • Pain
  • Pharmaceuticals
  • Cancer
  • Disease
  • Gastrointestinal
  • Therapeutic
  • Internet
  • Software
  • Game
  • Online Games-MMOG
  • Dermatology
  • DNA
  • Medical
  • Wound Care
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 362680

License Grant
The Licensee is party to an exclusive license with Licensor for the development and commercialization of Dexmedetomidine for use in the treatment of pain in humans in any dosage form for transdermal, transmucosal (including sublingual and intranasal), topical, enteral or pulmonary (inhalational) delivery, but specifically excluding delivery vehicles for administration by injection or infusion, worldwide, except for Europe, Turkey and the CIS (currently includes Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan), referred to herein as the Territory.
License Property
Dexmedetomidine means the compound known as “dexmedetomidine” or 4-((1S-1-(2,3-Dimethylphenyl)ethyl)-1H-imidazole including hydrates, stereoisomers, salts, and mixtures thereof.

Dex (dexmedetomidine) is a selective alpha-2 adrenergic agonist that has demonstrated sedative, analgesic and anxiolytic properties. Dex has an extensive commercial history of safe injectable use.

Field of Use
Field of use is for the treatment of pain in humans.

IPSCIO Record ID: 4717

License Grant
Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses.
License Property
The license is for the development and commercialization of non-injectable Dex (Dexmedetomidine) for use in the treatment of pain (including post-operative pain) in humans in any dosage form for transdermal, transmucosal (including sublingual and intranasal), topical, enteral or pulmonary (inhalational) delivery, the Licensed Dosage Forms, but specifically excluding delivery vehicles for administration by injection or infusion.

Dex is in a class of drugs called alpha-2 adrenergic agonists, which produce their effects by selectively activating the alpha-2 adrenergic receptors in the body and produce a broad range of effects depending on the specific drug and the alpha-receptors it activates, including anti-hypertensive, analgesic and sedative effects. In particular, Dex has demonstrated sedative, analgesic and anxiolytic properties in multiple preclinical and clinical studies, including the new drug application, or NDA, studies for Precedex®.

5217718 & 5124157 TRANSDERMAL ADMINISTRATION OF DEXMEDETOMIDINE – Method and device for administering dexmedetomidine transdermally

Field of Use
Under the Dexmedetomidine License Agreement, they were granted an exclusive license under Licensor Know-How and certain Patents to commercialize products in the territory.

“Field” means the treatment of pain in humans, including mild, moderate, or severe acute and chronic pain, alone or as an adjunct.

IPSCIO Record ID: 363963

License Grant
The Licensee is a party to an exclusive license agreement with Licensor for the development and commercialization of Fadolmidine for use as a human therapeutic, in any dosage form in the Territory.
License Property
Fadolmidine (MPV 2426) is an alpha2-adrenoceptor agonist. Fadolmidine displayed high affinity and full agonist efficacy at all three human alpha2-adrenoceptor subtypes (A, B and C). Various preclinical models of pain have been employed and have demonstrated fadolmidine potential as an analgesic, including its potential for use in neuropathies and post-operative pain.
Field of Use
Field of use is for a human therapeutic relating to pain.

IPSCIO Record ID: 3563

License Grant
Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses.

They entered into an  license agreement for the development and commercialization of Fado (Fadolmidine) for use as a human therapeutic, in any dosage form.

License Property
Fado is in a class of drugs called alpha-2 adrenergic agonists, which produce their effects by selectively activating the alpha-2 adrenergic receptors in the body and produce a broad range of effects depending on the specific drug and the alpha-receptors it activates, including anti-hypertensive, analgesic and sedative effects. Fado shows promise in neuropathic pain. It does not cross the blood brain barrier and this accounts for the targeting of Fado use for either IT administration for pain or anesthesia, or potentially for topical use to treat pain associated with regional nerve pain from underlying nerve damage, also called “neuropathies.”

U.S patent numbers (6313311; 7759496; 6479530; 6495584)

Field of Use
Fado is a product candidate to be used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Licensee intends to pursue as a topical product for local application to treat serious pain associated with neuropathies, especially of the lower extremities, which can occur in diabetic patients.

IPSCIO Record ID: 635

License Grant
The Russian Licensee and Korean Licensor entered into a this non-transferable, exclusive and royalty-bearing License and distribution agreement within the territory of shall mean the territory of the Former Soviet Republics  Armenia, Azerbaijan, Belorussia, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan.
License Property
Licensor has developed and owns all rights in computer programs of online game Requiem Online.  Requiem is a massively multiplayer online role-playing game.

Unless explicitly approved in writing by the Licensor, the Licensee shall have no right to sublicense.

Field of Use
This Exclusive Requiem Online License and Distribution Agreement is with respect to Intellectual Property rights which shall mean all patents, designs, utility models, copyrights, know-how, trade secrets, trademarks, service mark, trade dress and any other intellectual property rights in or related to the Game or Technical Information.  Licensee shall provide Game services only by way of the PC on-line method (excluding mobile access) using the Servers.

IPSCIO Record ID: 301547

License Grant
Licensor granted Polish Sublicensee an exclusive sublicense, even as to Licensor, for the patent rights Licensor licensed pursuant to the HPI License within the following countries Poland, Estonia, Latvia, Lithuania, Belarus, Ukraine, Moldova, Romania, Bulgaria, Serbia, Macedonia, Albania, Armenia, Azerbaijan, Georgia, Montenegro, Bosnia, Croatia, Slovenia, Slovakia, Czech Republic, Hungary, Chechnya, Uzbekistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Greece, Austria, and Russia. The sublicense agreement provides that Sublicensee must use commercially reasonable development efforts to attempt to develop and commercialize licensed products in the above mentioned territories.

Under the HPI License Licensor obtained the exclusive right to develop certain patented chemical compounds for use in the treatment of cancer anywhere in the world

License Property
Berubicin is an anthracycline, which is a class of drugs that are among the most powerful chemotherapy drugs known and as a class are effective against more types of cancer than any other class of chemotherapeutic agents.
Field of Use
The chemical compound is commonly known as Berubicin and used in the treatment of glioblastoma.  Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that begins within the brain.

IPSCIO Record ID: 218779

License Grant
The Licensor hereby grants to Licensee and to the Licensee of Spain, an exclusive right and license throughout the Territory, for Europe and for the U.S., sublicensable through multiple tiers and assignable, to practice under and otherwise use the Licensor Intellectual Property to research, Develop, Commercialize, make, have made, and otherwise exploit the Licensed Products for topical treatment of actinic keratosis, in the Field in the Territory.  Field means the treatment or prevention of any skin disorder or skin disease in humans, including any skin cancer treated by dermatologists.
License Property
The Licensor is developing a topical formulation of the Compound for the treatment of actinic keratosis – KX2-391.
Field of Use
The Licensees have experience in the development, marketing, promotion and sale of pharmaceutical products and will further develop and commercialize KX2-391 for the treatment of actinic keratosis and other skin conditions.

IPSCIO Record ID: 271161

License Grant
For the Research and Development License, Licensor grants to the German Licensee during the R&D Term a co-exclusive, with Licensor, right and license in the Territory under the Licensor Patents and the Licensor Know-How and Research Technology and under Licensors rights in the Joint Patents, Joint Research Technology and Joint Know-How, solely to conduct the Research, to characterize, optimize, research and develop the Development Compounds into Licensed Products in the Field and to make, have made and use Collaboration Compounds in the Field solely for research and development purposes in accordance with the Research and Development Plan and each Semi-Annual R&D Plan.

For the Commercialization License, Licensor grants to Licensee and its Affiliates a co-exclusive, with Licensor, right and license in the Territory under the Licensor Patents and the Licensor Know-How and Research Technology, and under Licensors rights in the Joint Know-How, Joint Research Technology and Joint Patents, to make, have made, import and use Licensed Products for use in the Field; and an exclusive, including with regard to Licensor right and license in the Territory under the Licensor Patents and the Licensor Know-How and Research Technology, and under Licensors rights in the Joint Know-How, Joint Research Technology and Joint Patents, to sell and offer for sale Licensed Products for use in the Field.

License Property
Licensor possesses proprietary technology and know-how related to the discovery, identification and synthesis of nicotinic agonists and has identified and applied for patents on certain nicotinic agonist compounds.

Licensed Product means any product, including any formulation thereof, containing or comprising a Development Compound.  Development Compound means any Collaboration Compound that has been selected as such hereunder, or any salt, solvate, prodrug form, inclusion complex, metabolite or other formulation thereof.

The technology means proprietary know-how of Licensee and its Affiliates concerning structure activity, relationships of Nicotinic Compounds and nicotinic receptors, pharmacophore mapping of nicotinic receptors and computational and quantum mechanical methods for use in the design, synthesis and evaluation of pharmacologically active agents, including but not limited to Nicotinic Compounds.

Compounds include -240312 Enema-Induction, and, -240312 Oral-Induction/Maintenance.

Field of Use
Field means the treatment or prevention in humans of one or more Indications.   Indication means ulcerative colitis; and other gastrointestinal and liver diseases.

Ulcerative colitis is a long-term condition that results in inflammation and ulcers of the colon and rectum.

IPSCIO Record ID: 369254

License Grant
Licensor grants to Licensee of the Russian Federation an exclusive right and license or  sublicense, as applicable, to the Licensed Technology to research, develop, make, have made, use, sell, offer for sale and import the Licensed Compound, Licensed Products and Licensed Product Biomarkers for the Field in the Licensee Territory.

This agreement includes a non-exclusive grant back to Licensor from Licensee.

License Property
Licensor develops, manufactures and commercializes products incorporating the proprietary compound known as tivozanib for the treatment of cancer.

Licensed Compound means the chemical compound 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea, otherwise known as tivozanib, and any and all pharmaceutically acceptable, acids, bases, esters, isomers, enantiomers, salts, stereoisomers, racemates, tautomers, polymorphs, complexes, chelates, crystalline and amorphous forms, prodrugs, solvates (including hydrates), metabolites and metabolic precursors, whether active or inactive, thereof.

Licensed patents are
Neuropilin-1 as a serum based biomarker;
Quinoline Derivatives and Quinazoline Derivatives having Azolyl Group; and,
Tivozanib Response Prediction.

Licensed Know-how is module 3 of the New Drug Application for tivozanib hydrochloride for the treatment of renal cell carcinoma.  

Licensed Product Biomarker means any and all biomarkers, including metabolite, DNA, RNA and protein profiles, discovered or developed by or on behalf of Licensor or Licensee during the Term that are for use with, including use in clinical testing of or use in any decision whether to prescribe, or relate to, are associated with or are correlated with patient populations who do or do not respond to treatment with, in the case of each, any one or more Licensed Products.

Tivozanib A potent, selective, long half-life vascular endothelial growth factor (“VEGF”) tyrosine kinase inhibitor (“TKI”) of VEGF receptors 1, 2 and 3. The Licensor is evaluating several potential paths for the development of tivozanib, including a second phase 3 trial of tivozanib in refractory renal cell carcinoma, or RCC.

Field of Use
The Field means the diagnosis, prevention and treatment of any disease or condition in humans other than non-oncologic diseases or conditions of the eye.

This agreement purpose is for the development, manufacturing and commercialization of Licensors small molecule vascular endothelial growth factor (YEGF) tyrosine kinase inhibitor tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions.

IPSCIO Record ID: 7364

License Grant
The Licensor and the Licensee of an India entered into a Patent and Technology License Agreement to License the Nimbus® intellectual property.

Under the Agreement, the Licensor grants the Licensee exclusive rights to use the Nimbus intellectual property in hydrophilic polyurethane foam for wound care applications and for securing intravenous tubings and catheters on products sold in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine, Uzbekistan, Russia and their territories and possessions.

License Property
The antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS® received de Novo FDA clearance in June 2009 and has been commercialized in traditional wound care applications.  Additional applications under development include advanced wound dressings, medical adhesives, and catheters.

NIMBUS® is based on non-toxic, long chain polymers with high charge density that provide superior efficacy via a physical action on microbes. By destroying bacteria at the cellular level, NIMBUS® eliminates the risk of developing drug resistance. The technology is highly effective against a multitude of bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE), two of the most significant antibiotic-resistant organisms responsible for hospital infections.

The Marks and Trademarks of Licensor include without limitation Quick-Med Technologies, QMT, Quick-Med, NIMBUS, and accompanying logos and trade dress, including the QMT Cross Official Logo

Patent
Intrinsically Bactericidal Absorbent Dressing and Method of Fabrication – IN/PCT/2001/00776/MUM
Method of Attaching An Antimicrobial Cationic Electrolyte To The Surface of A Substrate – PCT/US2006/32955
Polyelectrolyte Complex for Imparting Antimicrobial Properties to a Substrate – PCT/US2009/051163

Field of Use
Field means hydrophilic polyurethane foam in various shapes and sizes, used solely for wound care applications as primary or secondary dressings and for securing intravenous tubings and catheters.

IPSCIO Record ID: 266852

License Grant
The German Licensor grants an exclusive, except with regard to Licensor, world-wide right and license under the Licensor Patents and Licensor Know-How and Licensors rights in the Joint Patents, Joint Know-How and Joint Research Technology, to conduct the Research.

Licensor grants the exclusive right to use and to disclose to Third Parties all regulatory and clinical documentation and data developed by or on behalf of Licensor in the Territory in connection with this Agreement and required to be disclosed to Licensee under this Agreement, as reasonably necessary or desirable in connection with the development and commercialization of pharmaceutical products in the Field in the Rest of World or outside the Field throughout the world.

Licensor agrees to negotiate in good faith with Licensee concerning the terms of a license under the Licensor Patents and the Licensor Know-How covering the composition of matter or the use of the Terminated Compounds, to permit Licensee to research, develop, make, have made, import, use, sell and offer for sale the Terminated Compounds outside the Field throughout the world.

Licensor grants an exclusive, including with regard to Licensor, right and license in the Rest of World under the Licensor Patents and the Licensor Know-How and under Licensors rights in the Joint Patents, Joint KnowHow and Joint Research Technology, to research and develop, and to make, have made, import, use, sell and offer for sale pharmaceutical products, including Licensed Products, in the Field.

License Property
Licensor is engaged in the research, development and marketing of products for the treatment of, among other things, ulcerative colitis.

Licensed Product means any product, including any formulation thereof, containing or comprising a Development Compound.  Development Compound means any Collaboration Compound that has
been selected as such hereunder, or any salt, solvate, prodrug form, inclusion complex, metabolite or other formulation thereof.

The technology means proprietary know-how of Licensee and its Affiliates concerning structure activity, relationships of Nicotinic Compounds and nicotinic receptors, pharmacophore mapping of nicotinic receptors and computational and quantum mechanical methods for use in the design, synthesis and evaluation of pharmacologically active agents, including but not limited to Nicotinic Compounds.

Compounds include -240312 Enema-Induction, and, -240312 Oral-Induction/Maintenance.

Field of Use
Field means the treatment or prevention in humans of one or more Indications.   Indication means ulcerative colitis; and other gastrointestinal and liver diseases.

Licensee possesses proprietary technology and know-how related to the discovery, identification and synthesis of nicotinic agonists and has identified and applied for patents on certain nicotinic agonist compounds.

IPSCIO Record ID: 240601

License Grant
The Licensor of Denmark and Licensee are engaged in the development, production, and commercialization of pharmaceutical products and possess information and technology relating to the manufacture, use, and formulation of such products.

The Licensor of Denmark grants to an exclusive, even as to Licensor; in the Field in the Exclusive Territory to use the Licensor Product Deliverables and investigational new drug, or IND, Deliverables to make, have made under contract, use, develop and have developed under contract pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance and pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances, in each case during the Option Period solely in connection with the Initial Development Program.

Licensor grants an exclusive option during the Option Period to license the Licensed Technology for the research, development and Commercialization of Licensee Products on the terms set forth in this Agreement.

Licensor grants an exclusive, even as to Licensor, with the right to grant sublicenses, under the Licensed Technology to develop, have developed under contract, use, offer to sell, sell, have sold, distribute and import pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance and pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances in the Exclusive Territory in the Field.

Licensor grants an exclusive, except as to Licensor or its licensees or sublicensees, license, with the right to grant sublicenses, under the Licensed Technology to develop, have developed under contract, use, offer to sell, sell, have sold, distribute and import pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances in the Limited Territory in the Field.

Licensor grants an exclusive, even as to Licensor, license, with the right to grant sublicenses, under the Licensed Technology to make and have made under contract pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance and pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances for the Field in the Exclusive Territory.

Licensor grants a non-exclusive, license under the Licensed Technology, with the right to grant sublicenses, to make and have made under contract pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance and pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances for the Field outside the Exclusive Territory.

For the Isomer Option, Licensor grants a right of first refusal on an exclusive license, with the right to grant sublicenses, under any applicable Patent, Know-How or intellectual property other than Patents, Controlled by Licensor relating to any Isomer Product to develop, have developed under contract, make, have made under contract, use, offer to sell, sell, have sold, distribute and import such Isomer Product in the Field in the Exclusive Territory.

License Property
Single Entity Product means a pharmaceutical product containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance, and developed or manufactured by or on behalf of Licensee or Sublicensees using or referencing the Licensed Technology or any part thereof, or the use, manufacture or sale of which would, but for the licenses granted herein, infringe any Licensed Patents or intellectual property right other than Patents included in the Licensed Technology.

Combination Product means a pharmaceutical product containing Lomoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more additional active drug substances, and developed or manufactured by or on behalf of Licensee or Sublicensees using or referencing the Licensed Technology or any part thereof, or the use, manufacture or sale of which would, but for the licenses granted herein, infringe any Licensed Patents or intellectual property right other than Patents included in the Licensed Technology.

Isomer Product means a pharmaceutical product containing an isomer of Lornoxicam as either the single active drug substance or as an active drug substance in combination with one or more other active drug substances, developed solely by Licensor, and for which Licensor files an IND or equivalent filing in the Exclusive Territory within five years of the Effective Date.

Lornoxicam means the active drug substance known as lornoxicam, having the chemical structure set forth in this Agreement.

Lornoxicam, also known as chlortenoxicam, is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic (pain relieving), anti-inflammatory and antipyretic (fever reducing) properties.

Field of Use
Lornoxicam is a potent analgesic pain reliever, which makes it an attractive candidate for combination therapy.

IPSCIO Record ID: 26293

License Grant
The Licensee entered into a collaborative arrangement with a German Licensor.  The collaboration is focused on the development of drugs for a single therapeutic application-pain-but may involve multiple receptor families.  The Licensor is collaborating on the Alpha-2  Adrenergic Program to develop drugs for the alleviation of pain.
Field of Use
The rights granted apply to any human  pharmaceutical  product for  alleviating pain.

IPSCIO Record ID: 266853

License Grant
Licensor grants the German Licensee a non-transferable, exclusive license, with the right to sublicense, under the Licensed Product Patents to develop, commercialize, market, sell and distribute, but not manufacture, the Licensed Product in the Field in the Territory.

Licensor grants a non~exclusive, non•transferable license, with the right to sublicense, to use the Licensors Mark solely within the Territory and solely in connection with the sale of the Licensed Product in the Field.

License Property
The Licensed Product shall mean any pharmaceutical form, dosage, strength, or formulation of TheraCLEC-Total purchased from Licensor.

TheraCLEC-Total shall mean commercial formulations of that product currently known as TheraCLEC-Total consisting of the enzymes, lipase, amylase and protease.

Field of Use
The Field shall mean the treatment of symptoms (e.g. malabsorption or pain) directly caused by exocrine pancreatic insufficiency.  TheraCLEC is a novel orally delivered enzyme replacement therapy that is intended to replace digestive enzymes in patients suffering from pancreatic insufficiency.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.